Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT 1: Intra-Arterial Lidocaine and Steroid for Migraine
NCT06462781Phase 1Completed
- Sponsor
- Cooper University Health Care
- Start
- Mar 2024
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lidocaine and methylprednisolone in migraine, sponsored by Cooper University Health Care. Primary endpoint: Number of Adverse Events at 12 weeks. Started Mar 2024; status: completed.
02
Drugs
lidocainemethylprednisolone
03
Conditions
migraine
Beyond the preview
Go deeper on NCT06462781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462781.